You might to call them and see what's up. I'll hVe to look into it when my money hit nx week.
The Official CORMEDIX (CRMD)thread (run up to FDA approval has begun )
- Thread starter Tug life
- Start date
You might to call them and see what's up. I'll hVe to look into it when my money hit nx week.
krazykid18
Superstar
i forgot to look into it but did ur money clear and did u do it
I got in at 12 cents a few days ago thanks to this thread and some research. Im gonna be long on this..
Props
I pretty much liked the idea and the long term prospects of it.. Nothing number wise or anything
I dont really day trade I put money in and let that shyt sit there forever .. Or If I pick a loser I let it sit there until I can atleast break even lol
@krazykid18 , found this, this morning. looks like this might be a candidate for a pump and dump scam.
Regen BioPharma, Inc. Responds to Fake News Release
Still gonna take the risk myself and throw a few bucks at it. Just wanted to give you an heads up.
Regen BioPharma, Inc. Responds to Fake News Release
Still gonna take the risk myself and throw a few bucks at it. Just wanted to give you an heads up.
krazykid18
Superstar
$$$
Bloomberg - Are you a robot?
Pretty good interview.
Some shareholders wants JT to be more cocky tho. They want him to come out and flat out say, we will have one of, if not the highest selling drug of all time.
Time will tell tho..
Bloomberg - Are you a robot?
Pretty good interview.
Some shareholders wants JT to be more cocky tho. They want him to come out and flat out say, we will have one of, if not the highest selling drug of all time.
Time will tell tho..
from YMB:
Indeed, Reduce-IT was an outcome study. I'll repeat / paraphrase some comments regarding the critical importance of this point to investors, analysts, and most importantly the medical community.
Reduce-It was an outcome based study. "Does taking Vascepa together with statin result in lowering CV risk?" The outcome answer was an emphatic "Yes, by a 25-30% reduction". The method of action, while not fully understood, is multifactorial, not just lowering of triglycerides! This is critical to understand, and critical for AMRN to remind the world for two reasons: (1) as you point out, it allows for the broadest label possible irrespective of triglyceride level; and (2) because Reduce-It was outcome study not a lowering triglyceride study, no other drug or supplement can piggy-back off of Reduce-It to state that since their drug lowers triglycerides, then there is a CV risk reduction. AMRN / FDA, whether intentional or not, designed Reduce-IT as an outcome study specific to Vascepa, not applicable to any other drug that isn't pure EPA. Point 3: You hit this one on the head. JT is sending a message to the investment world, but more so to the FDA and potential suitors / competition, that the Reduce-IT was an outcome based study, so no piggy-backing on Reduce-It to suggest simply lowering triglycerides reduces CV risk. In short, Vascepa has a monopoly until patents run-out or another company can produce another Reduce-It like study for their own drug.
^^^from my understanding this is why Vascepa going to be such a HUGE deal. Its gonna be VERY beneficial to everyone with ANY kind of CV risk factors regardless of TG levels. Just look, were nearing a half bill in sales in 2019 while only being approved to treat TG levels that's over 500. Just picture what those sale numbers will look like if were approved for TG levels that's 135, or above. And that's just the tip of the iceberg, what many are thinking the ADCOM was needed is because the FDA needed more info because they see the Vascepa is beneficial no matter your TG level. So, what will those sells numbers look like if this is approved for anyone with any CV risk (elevated TG, Plaque build up, Obesity, Diabetic, etc, etc)? And this isn't yet factoring in the Evap study, the VA's Alzheimer's study (BRAVE is the name of the study if I remember right), and the different Cancer related benefits, etc, etc
Indeed, Reduce-IT was an outcome study. I'll repeat / paraphrase some comments regarding the critical importance of this point to investors, analysts, and most importantly the medical community.
Reduce-It was an outcome based study. "Does taking Vascepa together with statin result in lowering CV risk?" The outcome answer was an emphatic "Yes, by a 25-30% reduction". The method of action, while not fully understood, is multifactorial, not just lowering of triglycerides! This is critical to understand, and critical for AMRN to remind the world for two reasons: (1) as you point out, it allows for the broadest label possible irrespective of triglyceride level; and (2) because Reduce-It was outcome study not a lowering triglyceride study, no other drug or supplement can piggy-back off of Reduce-It to state that since their drug lowers triglycerides, then there is a CV risk reduction. AMRN / FDA, whether intentional or not, designed Reduce-IT as an outcome study specific to Vascepa, not applicable to any other drug that isn't pure EPA. Point 3: You hit this one on the head. JT is sending a message to the investment world, but more so to the FDA and potential suitors / competition, that the Reduce-IT was an outcome based study, so no piggy-backing on Reduce-It to suggest simply lowering triglycerides reduces CV risk. In short, Vascepa has a monopoly until patents run-out or another company can produce another Reduce-It like study for their own drug.
^^^from my understanding this is why Vascepa going to be such a HUGE deal. Its gonna be VERY beneficial to everyone with ANY kind of CV risk factors regardless of TG levels. Just look, were nearing a half bill in sales in 2019 while only being approved to treat TG levels that's over 500. Just picture what those sale numbers will look like if were approved for TG levels that's 135, or above. And that's just the tip of the iceberg, what many are thinking the ADCOM was needed is because the FDA needed more info because they see the Vascepa is beneficial no matter your TG level. So, what will those sells numbers look like if this is approved for anyone with any CV risk (elevated TG, Plaque build up, Obesity, Diabetic, etc, etc)? And this isn't yet factoring in the Evap study, the VA's Alzheimer's study (BRAVE is the name of the study if I remember right), and the different Cancer related benefits, etc, etc
really good presentation here.
Clinicians Live: New Opportunities to Reduce Residual Risk Beyond Statin Therapy
1st 2 mins it kinds of goes in on Statins a lil bit.
15 mins in- Reducing CV and TG levels
25 mins in- EPA effects on Plaque. HUGE HUGE HUGE
still watching.
Clinicians Live: New Opportunities to Reduce Residual Risk Beyond Statin Therapy
1st 2 mins it kinds of goes in on Statins a lil bit.
15 mins in- Reducing CV and TG levels
25 mins in- EPA effects on Plaque. HUGE HUGE HUGE
still watching.
Tug life
I stay fly like a guillemot
Just a friendly reminder, in our last CC Phoebe said "CorMedix believes that Neutrolin has the potential to be a best-in-class product without any serious competition in sight."
Jack Armstrong said . "I'm very pleased at the progress we have made, and while I'm not able to provide further details on this call, I can say that our production costs will generate pharma-like gross margins on U.S. sales."
Khoso "And we are convinced that it has the potential to be a best-in-class product. We have reconfirmed the significant unmet medical need and that practitioners consider current solutions inadequate. Healthcare providers are seeking a better solution."
Im not worried at all. I'm just accumulating shares below my average
Jack Armstrong said . "I'm very pleased at the progress we have made, and while I'm not able to provide further details on this call, I can say that our production costs will generate pharma-like gross margins on U.S. sales."
Khoso "And we are convinced that it has the potential to be a best-in-class product. We have reconfirmed the significant unmet medical need and that practitioners consider current solutions inadequate. Healthcare providers are seeking a better solution."
Im not worried at all. I'm just accumulating shares below my average
Big News outta Europe dropped early this morning:
Updated European guidelines recommend icosapent ethyl (Vascepa) for secondary prevention.
^^^^Link not working anymore for some reason.
9/2 BIG Medical Conference in Paris on EPA and reducing CV risk.
Also, even tho Vascepa isn't available in Europe yet, they just recommended it to treat folks with TG levels above 135! This makes Vascepa a Class 2A drug (higher rating than Statins).
Wheels are churning about the PDUFA (9/28) not being change "yet" even with the ADCOM being announced. Some are thinking 9/28 we may get expanded level for TG levels 135+ (if the date never gets pushed back of course). Then the ADCOM will address expanded label for ANY CV risk. Lipid Levels, TG Levels, Diabetic, Obesity, etc, etc <<<<<<<,That's HUGE!
Now this is a must read for any AMRN investors:
Amarin: Elucidating Bullish And Bearish Claims - Amarin Corporation plc (NASDAQ:AMRN) | Seeking Alpha
I think that covers most of the good news from the last 2 days. GLTA
Updated European guidelines recommend icosapent ethyl (Vascepa) for secondary prevention.
^^^^Link not working anymore for some reason.
9/2 BIG Medical Conference in Paris on EPA and reducing CV risk.
Also, even tho Vascepa isn't available in Europe yet, they just recommended it to treat folks with TG levels above 135! This makes Vascepa a Class 2A drug (higher rating than Statins).
Wheels are churning about the PDUFA (9/28) not being change "yet" even with the ADCOM being announced. Some are thinking 9/28 we may get expanded level for TG levels 135+ (if the date never gets pushed back of course). Then the ADCOM will address expanded label for ANY CV risk. Lipid Levels, TG Levels, Diabetic, Obesity, etc, etc <<<<<<<,That's HUGE!
Now this is a must read for any AMRN investors:
Amarin: Elucidating Bullish And Bearish Claims - Amarin Corporation plc (NASDAQ:AMRN) | Seeking Alpha
I think that covers most of the good news from the last 2 days. GLTA